Provided by Tiger Trade Technology Pte. Ltd.

CLIMB BIO INC

14.57
-0.4900-3.25%
Post-market: 14.40-0.1681-1.15%19:30 EDT
Volume:840.93K
Turnover:12.42M
Market Cap:834.29M
PE:-17.45
High:15.13
Open:14.86
Low:14.37
Close:15.06
52wk High:18.33
52wk Low:1.54
Shares:57.26M
Float Shares:41.60M
Volume Ratio:0.67
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8347
EPS(LYR):-0.8974
ROE:-27.10%
ROA:-18.45%
PB:3.48
PE(LYR):-16.24

Loading ...

Climb Bio is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 24

Climb Bio Price Target Maintained with a $20.00/Share by Wedbush

Dow Jones
·
Aug 19

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

Climb Bio Partner Mabworks Doses First Patient in China Phase 2 IgA Nephropathy Trial

Reuters
·
Aug 14

Truist Financial Sticks to Their Buy Rating for Climb Bio (CLYM)

TIPRANKS
·
Aug 13

Guggenheim Reaffirms Their Buy Rating on Climb Bio (CLYM)

TIPRANKS
·
Aug 10

RBC Capital Keeps Their Buy Rating on Climb Bio (CLYM)

TIPRANKS
·
Aug 08

Climb Bio Price Target Raised to $25.00/Share from $17.00 by Truist Securities

Dow Jones
·
Aug 07

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), Kodiak Sciences (KOD)

TIPRANKS
·
Aug 07

Climb Bio Initiates Phase 2 Clym116 Trial in IgA Nephropathy in Q3 2026

Reuters
·
Aug 06

Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate

Benzinga Earnings
·
Aug 06

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06

Climb Bio Q2 FY26 Net Loss Widens 55.73% to $13.5 Million

Reuters
·
Aug 06

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Aug 06

Climb Bio - Financing Extends Cash Runway into Second Half of 2028

THOMSON REUTERS
·
Aug 06

Climb Bio Inc Q2 Income from Operations USD -15.359 Million

THOMSON REUTERS
·
Aug 06

Climb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says

MT Newswires Live
·
Aug 03

Climb Bio Inc : RBC Initiates Coverage with Outperform Rating; Target Price $23

THOMSON REUTERS
·
Aug 03

Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst

TIPRANKS
·
Jul 31

Climb Bio is Maintained at Outperform by Wedbush

Dow Jones
·
Jul 27